Sjögren's disease trials in Spain

In Spain 8 Also abroad 80

8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Where
A Coruña, Barcelona, Madrid, Sabadell, Santander, Santiago de Compostela, Sevilla, Valencia
Age
18 years and over
People
570 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07621809 · EU 2025-522271-29-00
Phase 2Taking people
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Where
A Coruña, Barcelona, Madrid, Sabadell, Sevilla
Age
18 years to 100 years
People
344 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07737743 · EU 2025-524513-92-00
Phase 3Taking people
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Where
A Coruña, Barcelona, Córdoba, Madrid, Santiago de Compostela, Sevilla
Age
18 years to 75 years
People
250 worldwide
Run by
Vor Biopharma
See details and how to joinNCT07404865 · EU 2026-525556-28-00
Phase 2Not yet taking people in Spain
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
Where
Barcelona, Bilbao, Madrid, Málaga, Santiago de Compostela
Age
18 years and over
People
75 worldwide
Run by
argenx
See details and how to joinNCT07760818 · EU 2026-526218-10-00
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Sevilla
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Barcelona, Madrid, Majadahonda
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00
Phase 3Taking people
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Where
A Coruña, Bilbao, Córdoba, Madrid, Málaga, Santa Coloma de Gramenet, Sevilla
Age
18 years and over
People
844 worldwide
Run by
Amgen
See details and how to joinNCT06747949 · EU 2024-517513-32-00
No phaseTaking people
Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
Where
Pamplona
Age
18 years and over
People
300
Run by
Hospital Universitario Araba
See details and how to joinNCT07249060